<DOC>
	<DOCNO>NCT02416453</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability 3 vaccination schedule Ad26.ZEBOV MVA-BN-Filo administer IM heterologous prime-boost regimen .</brief_summary>
	<brief_title>A Study Assess Safety Tolerability Immunogenicity Three Prime-boost Regimens Candidate Prophylactic Vaccines Ebola Healthy Adults</brief_title>
	<detailed_description>This randomize , observer-blind , placebo-controlled , parallel-group , multicenter , Phase 2 study evaluate safety , tolerability immunogenicity 3 heterologous prime-boost regimen use Ad26.ZEBOV MVA-BN-Filo administer healthy adult participant Europe . The study consist screen period 12 week , vaccination period participant vaccinate baseline ( Day 1 ) , follow boost vaccination Days 29 , 57 85 , post-vaccination phase 6 month post-boost visit ( Days 209 , 237 265 ) . After unblinding , participant receive Ad26.ZEBOV MVA-BN-Filo continue study Day 365 visit assess long-term safety immunogenicity . Participants enroll 3 cohort : , Cohort 1 ( Participants receive Ad26.ZEBOV MVA-BN-Filo open-label fashion ) , Cohort 2 ( Participants randomize receive prime-boost vaccination either Ad26.ZEBOV follow MVA-BN-Filo , placebo 14:1 ratio ) Cohort 3 ( Participants randomize receive prime-boost vaccination either Ad26.ZEBOV follow MVA-BN-Filo , placebo 10:3 ratio ) . In Cohorts 2 3 , core immunogenicity assessment ( humoral cellular assay ) perform . In Cohort 2 , additional immunogenicity assessment do . In Cohort 1 , plasma blast response kinetics evaluate . Safety monitor study .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Must healthy Investigator 's clinical judgment basis medical history , physical examination , electrocardiogram ( ECG ) vital sign perform Screening Must healthy basis clinical laboratory test perform Screening . If result laboratory screening test outside normal reference range , participant may include Investigator judge abnormality deviation normal clinically significant appropriate reasonable population study Before randomization , woman must either childbearing potential practicing ( intend practice ) highly effective method birth control consistent local regulation regard use birth control method participant participate clinical study , begin least 28 day prior vaccination OR childbearing potential : postmenopausal ( great [ &gt; ] 45 year age amenorrhea least 2 year age amenorrhea least 6 month , serum follicle stimulate hormone ( FSH ) level &gt; 40 international unit per milliliter [ IU/L ] ) ; permanently sterilize ( example , bilateral tubal occlusion [ include tubal ligation procedure consistent local regulation ] , hysterectomy , bilateral salpingectomy , bilateral oophorectomy ) ; otherwise incapable pregnancy Woman childbearing potential must negative serum ( betahuman chorionic gonadotropin [ betahCG ] ) Screening negative urine betahCG pregnancy test immediately prior study vaccine administration Man sexually active woman childbearing potential vasectomy perform 1 year prior screen must willing use condom sexual intercourse begin prior enrollment Having receive candidate Ebola vaccine Diagnosed Ebola virus disease , prior exposure Ebola virus , include travel West Africa le 1 month prior screen . West Africa include limited country Guinea , Liberia , Mali , Sierra Leone Having receive experimental candidate adenovirus serotype 26 ( vector : Ad26 ) Modified Vaccinia Ankara ( MVA ) base vaccine past Known allergy history anaphylaxis serious adverse reaction vaccine vaccine product ( include constituent study vaccine include know allergy egg , egg product aminoglycosides Presence acute illness temperature great equal 38.0 C Day 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Ebola virus</keyword>
	<keyword>Ebola Viral Disease ( EVD )</keyword>
	<keyword>Filoviruses</keyword>
	<keyword>Monovalent vaccine</keyword>
	<keyword>Human adenovirus serotype 26 ( Ad26 ) express Ebola virus Mayinga variant glycoprotein ( Ad26.ZEBOV )</keyword>
	<keyword>Modified Vaccinia Virus Ankara - Bavarian Nordic Filo-vector ( MVA-BN Filo )</keyword>
	<keyword>Safety</keyword>
	<keyword>Immunogenicity</keyword>
</DOC>